NASDAQ:NBY - NovaBay Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.36 +0.07 (+24.56 %) (As of 05/23/2019 01:02 PM ET)Previous Close$0.2874Today's Range$0.27 - $0.4052-Week Range$0.23 - $3.74Volume1.09 million shsAverage Volume280,742 shsMarket Capitalization$6.74 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California. Receive NBY News and Ratings via Email Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:NBY Previous Symbol CUSIPN/A CIK1389545 Webhttp://www.novabaypharma.com/ PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares18,992,000Market Cap$6.74 million Next Earnings Date8/6/2019 (Estimated) OptionableNot Optionable NovaBay Pharmaceuticals (NASDAQ:NBY) Frequently Asked Questions What is NovaBay Pharmaceuticals' stock symbol? NovaBay Pharmaceuticals trades on the NASDAQ under the ticker symbol "NBY." How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) announced its quarterly earnings data on Thursday, March, 28th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The company earned $3.63 million during the quarter, compared to the consensus estimate of $3.80 million. View NovaBay Pharmaceuticals' Earnings History. When is NovaBay Pharmaceuticals' next earnings date? NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for NovaBay Pharmaceuticals. What is the consensus analysts' recommendation for NovaBay Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals. Has NovaBay Pharmaceuticals been receiving favorable news coverage? Media headlines about NBY stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Second Sight Medical Products (EYES), National Vision (EYE), Civista Bancshares (CIVB), Ceres (CERE), Benefitfocus (BNFT), Blackline (BL), BCB Bancorp (BCBP), AeroVironment (AVAV), American River Bankshares (AMRB) and JD Sports Fashion (JD). Who are NovaBay Pharmaceuticals' key executives? NovaBay Pharmaceuticals' management team includes the folowing people: Mr. Mark M. Sieczkarek, Chairman, CEO & Pres (Age 63)Mr. Justin M. Hall, Sr. VP & Gen. Counsel (Age 40)Mr. John J. McGovern, CFO, Treasurer & Principal Accounting OfficerDr. David W. Stroman Ph.D., Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board (Age 73)Mr. Lewis J. Stuart BA, MBA, Chief Commercial Officer (Age 59) How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NovaBay Pharmaceuticals' stock price today? One share of NBY stock can currently be purchased for approximately $0.3550. How big of a company is NovaBay Pharmaceuticals? NovaBay Pharmaceuticals has a market capitalization of $6.74 million. What is NovaBay Pharmaceuticals' official website? The official website for NovaBay Pharmaceuticals is http://www.novabaypharma.com/. MarketBeat Community Rating for NovaBay Pharmaceuticals (NASDAQ NBY)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 86 (Vote Outperform)Underperform Votes: 125 (Vote Underperform)Total Votes: 211MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What factors cause inflation to rise? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.